Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
February 24, 2022 at 04:34 pm IST
Share
Nautilus Biotechnology, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 50.32 million compared to USD 15.62 million a year ago.
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Companyâs products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Companyâs Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
NAUTILUS BIOTECHNOLOGY, INC. 
